Previous 10 | Next 10 |
FSD Pharma (HUGE +52% on licensing deal for veterinary drugs in dogs and cats.Zhongchao (ZCMD +49% after contract renewal with China Association of Health Promotion and Education and GlaxoSmithKline.Immatics N.V. (IMTX +24% on announcing a clinical data update fr...
-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to severe CABP can be managed effectively as outpatients with a 5-day, monotherapy regimen of oral XENLETA DUBLIN, Ireland, March 16, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics...
Nabriva Therapeutics PLC (NBRV) Q4 2020 Earnings Conference Call March 11, 2021, 16:30 ET Company Participants Gary Sender - CFO Theodore Schroeder - CEO & Director Jennifer Schranz - Chief Medical Officer Conference Call Participants Ed Arce - H.C. Wainwright & Co. Presentation Opera...
Nabriva Therapeutics (NBRV): Q4 GAAP EPS of -$1.11 misses by $0.33.Revenue of $2.46M (+645.5% Y/Y) beats by $1.86M.Shares -1% AH.Press Release For further details see: Nabriva Therapeutics EPS misses by $0.33, beats on revenue
-Relaunched XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community with 60 sales representatives- -Nabriva plans to initiate a Phase 1 clinical trial of XENLETA in patients with cystic fibrosis- -Conference call toda...
DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter a...
Gainers: Morphic (MORF) +106%.Aemetis (AMTX) +58%.SOS (SOS) +43%.Canaan (CAN) +41%.electroCore (ECOR) +37%.Vector Acquisition (VACQU) +37%.The9 (NCTY) +36%.One Stop Systems (OSS) +30%.HCI Group (HCI) +29%.ZK International (ZKIN) +27%.Losers: Athenex (ATNX) -52%.O...
Gainers: Morphic (MORF) +104%, electroCore (ECOR) +51%, Apollo Endosurgery (APEN) +24%, ASLAN Pharmaceuticals (ASLN) +23%, Satsuma Pharmaceuticals (STSA) +19%.Losers: Athenex (ATNX) -51%, Ontrak (OTRK) -48%, CorMedix (...
Nabriva Therapeutics (NBRV) trades 17.2% down premarket after entering into a definitive agreement with certain healthcare-focused and institutional investors for the purchase and sale of 10.4M shares and warrants to purchase up to 5.18M shares in a registered direct offer...
Athenex (ATNX) -55% on Q4 earnings release and on FDA rejection of oral paclitaxel application in breast cancer.Xtant Medical Holdings (XTNT) -16%.PLx Pharma (PLXP) -9% after FDA OKs PLx Pharma's Vazalore applications.Lixte Biotechnology Holdings (LIXT) -12%.Amer...
News, Short Squeeze, Breakout and More Instantly...
Nabriva Therapeutics plc Company Name:
NBRV Stock Symbol:
NASDAQ Market:
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment ...
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Na...
- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, ...